Replies to post #10219 on RespireRx Pharmaceuticals Inc (fka RSPI)

[Aiming4]

Do you feel that Roger's comments put us in a better position?

Possibly to probably.

Dr. Stoll frequently declines to answer questions or couches his answers to preserve confidentiality.

He would have done the same here had the situation warranted it.

Mgmt knows the details of the offers in the past and to date, so they are in the best position by far to know what is confidential info, what is common info, and what is inconsequential info.

Dr. Stoll's mention of a $30M to $50M upfronts range just told everyone that has submitted a lower offer, or has yet to submit one, what the ante is to get in the game.

When it gets to crunch time in the deal negotiations, BPs aren't going to cap their offers at $50M because of a comment Dr. Stoll made on an investor CC early in the offer process.

[moosedogger]

>> I can say that I would expect the upfronts to be somewhat higher than originally anticipated. We view CX717 as critical to the development of our platform and are vigorously pursuig the best deal possible."<<

The cynic in me says, "somewhat higher"?- Oh, you mean like $31 million?

So, you are now "vigorously pursuing the best deal"?- Sure, just like you did when you made us all bagholders by not only giving away the stock at $1 and $2, but adding insult to injury by throwing cheap warrants into the deal to make it an even bigger travesty.

No way- not even close- no contest.

Hands down winner is Roger saying $30-$50 million in upfronts.

I applaud his statement as is- if he expressed it as in your suggested version, it just sounds like he's already caved, given up, surrendered, etc. as it just comes across weak, imo.

It would be one thing if Stoll listed all the things the $30-$50 million would buy, but he didn't- he just expressed what he's looking for in upfronts.

This is confidence boosting, reassuring, etc. because:

1. Stoll is not a BS artist- he's credible probably to the point of being too low-key, understated, etc.

2. This is consistent with the extra punch virtually all of the biotech deals being done since the first of the year or earlier are getting- this is the richest bio deal making market in years.

The BP deal is Stoll's "white whale"- he really needs to land it this time as it's been eluding him for years.

I think he's got it just right- now it just needs to get done.

[vsualyzprofits]

Iggs,

This is an excellently written response, to quote:

"There is significant interest and we are exploring the best deal for Cortex from both a financial and strategic perspective. We do not think all interested parties have come forward and do not feel it is appropriate to disclose a range at this time. This would not be fair to prospective counterparties or maximize value for our shareholders. I can say that I would expect the upfronts to be somewhat higher than originally anticipated. We view CX717 as critical to the development of our platform and are vigorously pursuig (sic) the best deal possible."

How long did it take you to compose these exact words? They are well thought out and I’m sure this wasn’t your first draft (although you could brush up on your spelling a little bit). Remember Roger was responding to the question, on the spot, without the benefit of having time to sit down and slowly think through his response. IMHO, his response was more than adequate given the circumstances.

Regards, Judy

P.S. For those of you wondering what the (sic) stands for, in the legal field anytime you are referring to a quote, you always put (sic) after a misspelled word to indicate to the judge that this was in the original quote and not a typo on your part.